Pancreatic cancer 1

Common Name(s)

Pancreatic cancer 1

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 1" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Pancreatic cancer 1" for support, advocacy or research.

Logo
Pancreatic Cancer Action Network

The Pancreatic Cancer Action Network is a nationwide network of people dedicated to working together to advance research, support patients and create hope for those affected by pancreatic cancer.

http://www.pancan.org

Last Updated: 20 Feb 2013

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Pancreatic cancer 1" returned 230 free, full-text research articles on human participants. First 3 results:

miR-212 promotes pancreatic cancer cell growth and invasion by targeting the hedgehog signaling pathway receptor patched-1.
 

Author(s): Chenchao Ma, Kate Nong, Bo Wu, Bo Dong, Yueqing Bai, Hongda Zhu, Weiwei Wang, Xinyu Huang, Zhou Yuan, Kaixing Ai

Journal:

 

microRNAs (miRNAs) are a class of small non-coding RNAs that play important roles in carcinogenesis. In the present study, we investigated the effect of miR-212 on pancreatic ductal adenocarcinoma (PDAC) and its target protein.

Last Updated: 9 Jul 2014

Go To URL
Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study.
 

Author(s): Takuji Okusaka, Masafumi Ikeda, Akira Fukutomi, Yoshikazu Kobayashi, Kazuhiro Shibayama, Takatoshi Takubo, Jennifer Gansert

Journal: Jpn. J. Clin. Oncol.. 2014 May;44(5):442-7.

 

Previous Phase 1 studies have shown the acceptable safety profile of ganitumab-a fully human monoclonal antibody to insulin-like growth factor Type 1 receptor-in patients with advanced solid tumors. However, ganitumab 20 mg/kg in combination with gemcitabine had not been administered ...

Last Updated: 30 Apr 2014

Go To URL
(+)-Grandifloracin, an antiausterity agent, induces autophagic PANC-1 pancreatic cancer cell death.
 

Author(s): Jun-ya Ueda, Sirivan Athikomkulchai, Ryuta Miyatake, Ikuo Saiki, Hiroyasu Esumi, Suresh Awale

Journal:

 

Human pancreatic tumors are known to be highly resistant to nutrient starvation, and this prolongs their survival in the hypovascular (austere) tumor microenvironment. Agents that retard this tolerance to nutrient starvation represent a novel antiausterity strategy in anticancer drug ...

Last Updated: 31 Dec 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Pancreatic cancer 1" returned 3 free, full-text review articles on human participants. First 3 results:

Significance of caveolin-1 regulators in pancreatic cancer.
 

Author(s): Tao Chen, Liang Liu, Hua-Xiang Xu, Wen-Quan Wang, Chun-Tao Wu, Wan-Tong Yao, Xian-Jun Yu

Journal: Asian Pac. J. Cancer Prev.. 2013 ;14(8):4501-7.

 

Caveolin-1 is a scaffold protein on the cell membrane. As the main component of caveolae, caveolin-1 is involved in many biological processes that include substance uptake and transmembrane signaling. Many of these processes and thus caveolin-1 contribute to cell transformation, tumorigenesis, ...

Last Updated: 2 Oct 2013

Go To URL
Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.
 

Author(s): M Mimeault, S K Batra

Journal: Gut. 2008 Oct;57(10):1456-68.

 

Recent progress on pancreatic stem/progenitor cell research has revealed that the putative multipotent pancreatic stem/progenitor cells and/or more committed beta cell precursors may persist in the pancreatic gland in adult life. The presence of immature pancreatic cells with stem ...

Last Updated: 15 Sep 2008

Go To URL
Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis.
 

Author(s): R J Stevens, A W Roddam, V Beral

Journal: Br. J. Cancer. 2007 Feb;96(3):507-9.

 

We conducted a systematic review of the risk of pancreatic cancer in people with type I and young-onset diabetes. In three cohort and six case-control studies, the relative risk for pancreatic cancer in people with (vs without) diabetes was 2.00 (95% confidence interval 1.37-3.01) ...

Last Updated: 7 Feb 2007

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1
 

Status: Recruiting

Condition Summary: Metastatic Pancreatic Cancer; ERCC1

 

Last Updated: 30 Jan 2012

Go to URL
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
 

Status: Recruiting

Condition Summary: Adult Anaplastic Astrocytoma; Adult Anaplastic Ependymoma; Adult Anaplastic Oligodendroglioma; Adult Brain Stem Glioma; Adult Ependymoblastoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Nasal Type Extranodal NK/T-Cell Lymphoma; Adult Pineal Gland Astrocytoma; Adult Solid Neoplasm; AIDS Related Immunoblastic Lymphoma; AIDS-Related Burkitt Lymphoma; AIDS-Related Diffuse Large Cell Lymphoma; AIDS-Related Diffuse Mixed Cell Lymphoma; AIDS-Related Diffuse Small Cleaved Cell Lymphoma; AIDS-Related Hodgkin Lymphoma; AIDS-Related Lymphoblastic Lymphoma; AIDS-Related Lymphoma; AIDS-Related Primary Central Nervous System Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-Cell Lymphoma; Cutaneous B-Cell Non-Hodgkin Lymphoma; Extensive Stage Small Cell Lung Carcinoma; Extra-Adrenal Paraganglioma; Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Gastrin-Producing Neuroendocrine Tumor; Hepatic Complication; Hepatosplenic T-Cell Lymphoma; Intraocular Lymphoma; Lung Carcinoid Tumor; Lymphomatous Involvement of Non-Cutaneous Extranodal Site; Male Breast Carcinoma; Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Metastatic Adrenal Gland Pheochromocytoma; Metastatic Gastrointestinal Neuroendocrine Tumor G1; Nasal Cavity Inverted Papilloma; Nodal Marginal Zone Lymphoma; Olfactory Neuroblastoma; Pancreatic Glucagonoma; Pancreatic Insulinoma; Pancreatic Polypeptide Tumor; Poorly Differentiated Thyroid Gland Carcinoma; Recurrent Adrenal Gland Pheochromocytoma; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Brain Neoplasm; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult Soft Tissue Sarcoma; Recurrent Adult T-Cell Leukemia/Lymphoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Colon Carcinoma; Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma; Recurrent Gastrointestinal Neuroendocrine Tumor G1; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Inverted Schneiderian Papilloma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Lip Basal Cell Carcinoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Melanoma; Recurrent Merkel Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma to the Neck With Occult Primary; Recurrent Mycosis Fungoides and Sezary Syndrome; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Nasal Type NK/T-Cell Lymphoma; Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Recurrent Nasopharyngeal Undifferentiated Carcinoma; Recurrent Non-Small Cell Lung Carcinoma; Recurrent Olfactory Neuroblastoma; Recurrent Oral Cavity Adenoid Cystic Carcinoma; Recurrent Oral Cavity Mucoepidermoid Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Oropharyngeal Undifferentiated Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Pancreatic Neuroendocrine Carcinoma; Recurrent Prostate Carcinoma; Recurrent Rectal Carcinoma; Recurrent Renal Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Recurrent Small Cell Lung Carcinoma; Recurrent Small Lymphocytic Lymphoma; Recurrent Thyroid Gland Carcinoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Regional Adrenal Gland Pheochromocytoma; Regional Gastrointestinal Neuroendocrine Tumor G1; Small Intestinal Lymphoma; Somatostatin-Producing Neuroendocrine Tumor; Splenic Marginal Zone Lymphoma; Squamous Cell Carcinoma Metastatic to the Neck With Occult Primary; Stage III Adult Soft Tissue Sarcoma; Stage III Bladder Cancer; Stage III Hypopharyngeal Squamous Cell Carcinoma; Stage III Laryngeal Squamous Cell Carcinoma; Stage III Laryngeal Verrucous Carcinoma; Stage III Lip and Oral Cavity Squamous Cell Carcinoma; Stage III Lip Basal Cell Carcinoma; Stage III Major Salivary Gland Carcinoma; Stage III Merkel Cell Carcinoma; Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage III Nasal Type NK/T-Cell Lymphoma; Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Stage III Nasopharyngeal Undifferentiated Carcinoma; Stage III Oral Cavity Adenoid Cystic Carcinoma; Stage III Oral Cavity Mucoepidermoid Carcinoma; Stage III Oral Cavity Verrucous Carcinoma; Stage III Oropharyngeal Squamous Cell Carcinoma; Stage III Oropharyngeal Undifferentiated Carcinoma; Stage III Pancreatic Cancer; Stage III Prostate Cancer; Stage III Renal Cell Cancer; Stage III Thyroid Gland Follicular Carcinoma; Stage III Thyroid Gland Papillary Carcinoma; Stage IIIA Breast Cancer; Stage IIIA Colon Cancer; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIA Rectal Cancer; Stage IIIA Skin Melanoma; Stage IIIB Breast Cancer; Stage IIIB Colon Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IIIB Rectal Cancer; Stage IIIB Skin Melanoma; Stage IIIC Breast Cancer; Stage IIIC Colon Cancer; Stage IIIC Rectal Cancer; Stage IIIC Skin Melanoma; Stage IV Adult Soft Tissue Sarcoma; Stage IV Bladder Cancer; Stage IV Breast Cancer; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Merkel Cell Carcinoma; Stage IV Nasal Type NK/T-Cell Lymphoma; Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Stage IV Nasopharyngeal Undifferentiated Carcinoma; Stage IV Non-Small Cell Lung Cancer; Stage IV Pancreatic Cancer; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Skin Melanoma; Stage IVA Basal Cell Lip Carcinoma; Stage IVA Colon Cancer; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVA Oral Cavity Adenoid Cystic Carcinoma; Stage IVA Oral Cavity Mucoepidermoid Carcinoma; Stage IVA Oral Cavity Verrucous Carcinoma; Stage IVA Oropharyngeal Squamous Cell Carcinoma; Stage IVA Oropharyngeal Undifferentiated Carcinoma; Stage IVA Rectal Cancer; Stage IVA Thyroid Gland Follicular Carcinoma; Stage IVA Thyroid Gland Papillary Carcinoma; Stage IVB Basal Cell Lip Carcinoma; Stage IVB Colon Cancer; Stage IVB Laryngeal Squamous Cell Carcinoma; Stage IVB Laryngeal Verrucous Carcinoma; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVB Oral Cavity Adenoid Cystic Carcinoma; Stage IVB Oral Cavity Mucoepidermoid Carcinoma; Stage IVB Oral Cavity Verrucous Carcinoma; Stage IVB Oropharyngeal Squamous Cell Carcinoma; Stage IVB Oropharyngeal Undifferentiated Carcinoma; Stage IVB Rectal Cancer; Stage IVB Thyroid Gland Follicular Carcinoma; Stage IVB Thyroid Gland Papillary Carcinoma; Stage IVC Basal Cell Lip Carcinoma; Stage IVC Laryngeal Squamous Cell Carcinoma; Stage IVC Laryngeal Verrucous Carcinoma; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVC Major Salivary Gland Carcinoma; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Stage IVC Oral Cavity Adenoid Cystic Carcinoma; Stage IVC Oral Cavity Mucoepidermoid Carcinoma; Stage IVC Oral Cavity Verrucous Carcinoma; Stage IVC Oropharyngeal Squamous Cell Carcinoma; Stage IVC Oropharyngeal Undifferentiated Carcinoma; Stage IVC Thyroid Gland Follicular Carcinoma; Stage IVC Thyroid Gland Papillary Carcinoma; T-Cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Thyroid Gland Medullary Carcinoma; Thyroid Gland Undifferentiated (Anaplastic) Carcinoma; Tongue Carcinoma; Waldenstrom Macroglobulinemia

 

Last Updated: 15 Dec 2014

Go to URL
Pancreatic Cancer Early Detection Program
 

Status: Recruiting

Condition Summary: Pancreatic Cancer; Pancreas Cancer; Pancreatic Adenocarcinoma; Familial Pancreatic Cancer; BRCA 1/2; HNPCC; Lynch Syndrome; Hereditary Pancreatitis; FAMMM; Familial Atypical Multiple Mole Melanoma; Peutz Jeghers Syndrome

 

Last Updated: 30 Jul 2014

Go to URL